Is there a reasonable risk/reward at around the current share price of $5.18 considering the recent news announcements on 30% cut in staff to control costs, while focusing on highest priority research (trials)?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.